Tel Aviv University researchers have developed a low-cost blood test that detects lung cancer by analyzing optical DNA fingerprints, achieving 93.1% sensitivity and 90.3% specificity.
Concert has issued a coverage policy deeming the EsoGuard Esophageal DNA Test medically necessary for eligible patients, with multiple client health plans now adopting the policy.
As Cyclospora infections surge in the US, laboratories face increased pressure to quickly differentiate cases, with the CDC reporting 1,947 confirmed infections and 98 hospitalizations across nine states as of July 24.
Researchers at Johns Hopkins validated an AI-powered blood test that accurately detects liver cancer in diverse populations, using the DELFI platform to analyze cell-free DNA fragments.
A Quest Diagnostics study of 1.5 million women found those with bacterial vaginosis are over three times more likely to have a non-viral STI, highlighting the need for comprehensive diagnostic testing.
HerAnova Lifesciences reported real-world data on its HerResolve multi-omic blood test for endometriosis at the 2026 Midwest Reproductive Annual Symposium, showing consistent performance across 197 cases in diverse clinical settings.
A new ultrasensitive blood test may detect Sjögren’s disease more than 10 years before symptoms appear by identifying chronically elevated interferon alpha levels in patient blood samples.
Labcorp has announced the upcoming launch of the Marker by Labcorp Genetic Health Panel, which will analyze 163 genes linked to over 100 medically actionable conditions, with results supported by licensed genetic counselors.
Imperial College London has begun integrating C2N’s PrecivityAD2 blood test into primary care pathways for Alzheimer’s diagnosis, as part of the BEAD-PC study and the Davos Alzheimer’s Collaborative initiative.
Research presented at ADLM 2026 indicates immunoassays may significantly underestimate HbA1c in patients with sickle cell trait, suggesting HPLC offers more reliable diabetes screening for populations with hemoglobin variants.
Elevated donor-derived cell-free DNA levels are linked to higher kidney transplant failure risk, suggesting earlier detection of allograft injury before loss of kidney function.
The Cystic Fibrosis Base assay has received IVDR accreditation, ensuring high standards for detecting cystic fibrosis mutations.
The BD BACTEC FXI Culture System reduces detection time for bloodstream infections by approximately three hours compared to previous models.